Download App

Log in to access Online Inquiry
Company Overview More
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
CEO: Onsi J.D., Douglas E.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > LPTX Leap Therapeutics > Detailed Quotes

LPTX Leap Therapeutics

1.220-0.100-7.58%
Close 05/18 20:00 ET
1.22000.00%
Post Mkt Price 05/18 16:00 ET
High
1.300
Open
1.260
Turnover
1.05M
Low
1.190
Pre Close
1.320
Volume
842.82K
Market Cap
107.75M
P/E(TTM)
Loss
52wk High
4.170
Shares
88.32M
P/E(Static)
Loss
52wk Low
0.920
Float Cap
78.61M
Bid/Ask %
33.33%
Historical High
10.250
Shs Float
64.43M
Volume Ratio
0.64
Historical Low
0.573
Dividend TTM
--
Div Yield TTM
--
P/B
1.09
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.31%
Amplitude
8.33%
Avg Price
1.248
Lot Size
1
Float Cap
78.61M
Bid/Ask %
33.33%
Historical High
10.250
Shs Float
64.43M
Volume Ratio
0.64
Historical Low
0.573
Dividend TTM
--
P/B
1.09
Dividend LFY
--
Turnover Ratio
1.31%
Amplitude
8.33%
Avg Price
1.248
Lot Size
1
Price Forecast

No Data

News

Comment